BioCentury
ARTICLE | Company News

Hologic diagnostic news

December 16, 2013 8:00 AM UTC

Hologic entered into a nomination and standstill deal with activist investor Carl Icahn. The company appointed Jonathan Christodoro and Samuel Merksamer, both managing directors at Icahn Capital L.P., as directors. Christodoro is also a director at Enzon Pharmaceuticals Inc. (NASDAQ:ENZN, Bridgewater, N.J.). Hologic's board now comprises 11 directors. As part of the deal, Hologic agreed to include Icahn's designees in its slate of nominees for election at its 2014 annual meeting. Icahn agreed to not solicit proxies regarding any matter to come before the annual meeting, including the election of directors. Icahn also agreed to not acquire additional shares of the company's voting stock. Icahn owns about 34.2 million shares of Hologic common stock, about a 12.5% stake. The standstill period began on Dec. 8 and will end on the later of the completion of the 2014 annual meeting and the date on which there is no Icahn designee on the company's board. ...